Topotecan Episcleral Plaque for Treatment of Retinoblastoma
Status:
Recruiting
Trial end date:
2030-10-15
Target enrollment:
Participant gender:
Summary
This single site, single-arm, non-randomized, dose escalation phase I toxicity clinical trial
will assess primarily the safety and secondarily the efficacy of episcleral topotecan in
patients with active residual or recurrent intraocular retinoblastoma in at least one eye
following completion of first-line therapy.